Key Takeaways
- Record quarter, margin milestone hit: Revenue reached a record ₹361.8 cr and EBITDA margin touched the promised double-digit level of 10.5%, driven by strong execution and a favorable export mix.
- Order backlog consumed, rebuild promised: Backlog fell from ₹2,400 cr to ₹2,170 cr as orders were consumed during the year; management expects "very solid updates" on a rebuild within the next quarter as key programs progress.
- Inorganic strategy nearing material impact: Advanced-stage acquisition discussions are underway for a target in the $40M–$100M revenue range, with an update expected on the next call.
- Working capital turned a corner: Net working capital improved to 79 days, the lowest in four quarters, generating positive free cash flow of nearly ₹129 cr in Q4.
- What to watch next quarter: Whether the promised order backlog rebuild materializes with concrete program wins, the pace of new logo additions in healthcare, and any announcement on the inorganic front.
Order Book & Demand Pipeline
- Backlog drawdown: The ₹230 cr decline in order backlog reflects consumption of orders during a 40%+ growth year, not demand weakness; management characterizes the pipeline as robust and expects key programs to rebuild the book.
- Long-cycle visibility: Orders have long windows, so the current 1.8x book-to-bill does not capture the full revenue visibility; new client engagements typically start with small projects and NPIs before scaling to volume production.
- Rebuild catalyst: Strategic programs, including advanced air mobility engagements, are "very much on track" and form a core part of the coming fiscal year's expectations.
- Order intake trajectory: Higher traction from existing clients is expected to drive increased order intake in coming quarters, with new clients contributing as they move from prototyping to production.
Montalbano: "I would definitely expect to have some very solid updates within the next quarter for sure."
Segment Performance & Mix Shift
| Segment | Trend | Commentary |
|---|---|---|
| Aerospace & Defense | ▲ Growing | Higher share of revenue in FY24 vs FY23; driven by general increase in global defense funding, not specifically Middle East tension. Opportunities in Middle East and India. |
| Industrial | ▼ Declined | Decline due to a key client degrowing; recovery expected as new clients come on board. |
| Medical/Healthcare | ▬ Early stage | Working on key opportunities; a key client announcement expected. Significant upside potential and new logos anticipated throughout FY25. |
| Exports | ▲ Mix improving | Export share higher in Q4; expected to shift from 66-34 to 70-30 in FY25, supporting margin improvement. |
- Box build vs PCBA: Box build revenue declined due to program-specific requirements and customer preferences, not margin considerations; there is no margin difference between the two. [12-13]
- Israel exposure resilient: Business dependent on Israel customers or supply chain continues to perform well despite the Israel-Hamas war.
Margins & Profitability
- Q4 margin walk: EBITDA margin reached 10.5%, driven by favorable product mix with higher revenue from non-India customers; sustainability depends on quarterly mix, but full-year improvement is expected.
- Employee cost headwind: Year-on-year increase in employee costs was a planned investment in headcount to strengthen the team; as scale is added, costs will not increase linearly and absorption benefits will kick in.
- BEL contract drag: BEL orders carry substantially lower margins; as they become a smaller percentage of mix and are replaced by other customer orders, margins will expand. BEL remains a key client.
- Finance cost persistence: Despite repaying external debt, internal loans remain at market rates; a one-time forex loss was also booked. Finance costs are expected to decline over the next year.
- Margin guidance: Sequential softness expected in the first couple of quarters due to seasonality; full-year margins will improve year-on-year but will not reach 11–12%. [10-11]
Kulkarni: "Our decision making will be the return on capital employed rather than margins."
Balance Sheet & Cash Flow
- Free cash flow inflection: Generated positive FCF of nearly ₹129 cr in Q4, though holidays in the last week of March pushed some collections into April. Full-year FCF was negative ₹104 cr, described as manageable given 40%+ growth.
- Working capital improvement: Net working capital improved to 79 days, the lowest in four quarters, driven by DSO reduction to 57 days and a 20-day inventory reduction in Q4. Near-term target is to maintain ~90 days.
- Customer advances declining: No new significant advances; the balance will continue to decline as previous advances (primarily from BEL) are squared off with revenue. Supply chain easing has also reduced customers' willingness to give advances.
- IPO proceeds deployment: Half of remaining IPO proceeds are earmarked for working capital, with the rest for capex, general corporate purposes, and M&A. As funds are used, benefits will convert into higher operating costs.
Strategic Initiatives & Investments
- Capacity expansion: Two new facilities inaugurated: a precision machining facility in Bangalore (greenfield, with large key clients) and a Mysore facility expanding EMS, cable and wire harness capacity.
- Leadership build-out: A CTO has been hired to drive build-to-spec design and manufacturing capability; the full management team is now in place after ~12 months of recruiting.
- Supply chain and sales investments: Investments made in supply chain leadership and mid-level talent for alternate component design, plus key sales hires for engagement with industry-leading OEMs.
- Inorganic strategy: Advanced-stage discussions with a potential acquisition target in the $40M–$100M annual revenue sweet spot; the acquisition will add capability, capacity, and potential geographic offerings. An update is expected on the next call.
- Build-to-spec differentiation: Integrated design and manufacturing solutions are gaining momentum as a core differentiator; very strategic programs combining these capabilities will be announced.
Montalbano: "We see this as having what I call material impact going forward as we continue to add capability, capacity, and also potential geo-offerings."
Segment Mix Ambition
- Long-term target: Management aims to reshape the portfolio over 2–3 years toward 25% medical, 25% industrial, and 50% aerospace and defense, diversifying away from the current A&D concentration.
- New logo progress: Two new logos were added in FY24; a couple more are likely in the coming quarter, with healthcare expected to contribute new logos throughout FY25.
- Sector adjacencies: Management will evaluate opportunities in EVs, automotive, and communications where the right value profile exists.
Montalbano: "Ideally, we would like to get it where 25% of the business is 25% medical, 25% industrial, and then maybe A and B make up 50%."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue CAGR | Maintain 30% on a three-year basis | Rolling three-year basis |
| Order backlog rebuild | "Very solid updates" expected | Within the next quarter |
| EBITDA margin | Full-year improvement year-on-year, but not reaching 11–12%; sequential softness in early quarters | FY25 [10-11] |
| Export mix | Shift from 66-34 to 70-30 | FY25 |
| Working capital | Maintain net working capital cycle of 90–100 days | End of FY25 |
| Finance costs | Expected to decline | Over the next year |
| ROCE target | ~15% | Within a couple of years [16-17] |
| ROCE target (steady state) | ~25% | In about 5 years |
| Inorganic update | Announcement on acquisition target | Next earnings call [12-13] |
| Segment mix target | 25% medical, 25% industrial, 50% A&D | In about 2–3 years |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Revenue | ₹361.8 cr, +30.5% YoY |
| Full-year revenue | ₹1,191.9 cr, +43.2% YoY |
| Operating profit | ₹38 cr, +19.2% YoY |
| EBITDA margin | 10.5% |
| Profit after tax | ₹22.7 cr, +80.7% YoY |
| PAT margin | 6.3%, +175 bps YoY |
| Order backlog | ₹2,170.5 cr, down ₹262 cr YoY |
| Order backlog-to-sales ratio | ~1.8x, vs ~2.9x at end of FY23 (per an analyst's math) |
| Order wins | ~half of prior-year order wins |
| Net working capital | 79 days, lowest in four quarters |
| Average net working capital (full year) | >100 days |
| DSO | 57 days |
| Free cash flow (Q4) | ~₹129 cr positive |
| Free cash flow (full year) | negative ₹104 cr |
| Fixed asset turnover | 8.6x, improved from 6.8x |
| Export-to-domestic revenue mix | Two-thirds export, one-third domestic |
| Defense segment revenue share | 56% of total, segment grew ~78% |
| Box build share of order book | 25%, down from 35% in FY24 |
| BEL order book remaining | ~₹5.5 cr, down from ~₹95 cr at start of FY24 |
| Customer advances | 25 days of advances |
| Revenue seasonality | ~45% H1, ~55% H2 |
| ROCE target | ~15% within a couple of years, ~25% steady state |
| Inorganic sweet spot | $40 mn to $100 mn annual revenue |
| Ideal segment mix target (2–3 years) | 25% medical, 25% industrial, 50% aero & defense |